

IPO Expected Timetable#

Stock Code	Stock Name	Closing Date*	Allotment Date	Listing Date
03347	TIGERMED	2020/07/30	2020/08/06	2020/08/07

#IPO listed above are those with fundraising amount more than HK\$500M. For more IPO information, please visit www.cfs.com.hk or contact our account executives or customer service officers

* Applicants please deposit the full amount / margin into the bank account of Celestial Securities Limited no later than 12:00 p.m. in case of cash payment or 4:00 p.m. in case of cheque payment on the Closing Date. If your margin financing is approved and your application for Public Offer Shares is successful (in whole or in part), please deposit the remaining amount of margin no later than 4:00 p.m. on the allotment date.

Hangzhou Tigermed Consulting Co., Ltd. (3347.HK)

Share Offer Highlights

Total number of Offer Shares:	107,065,100 H Shares (subject to the Over-allotment Option)
- Number of Public Offer Shares:	5,888,600 H Shares (subject to reallocation)
- Number of Placing Shares:	101,176,500 H Shares (subject to reallocation and the Over-allotment Option)
Number of Shares per Lot:	100 Shares
Offer Price:	HKD 88.00 – 100.00 per Share
2019 Historical P/E ratio:	83.74x – 95.15x
Sponsor:	BofA SECURITIES, Haitong, Citic Securities, CICC

Company Overview

The Company is a leading China-based provider of comprehensive biopharmaceutical R&D services, with an expanding global presence. According to the Frost & Sullivan Report, it was the largest clinical CRO in China in terms of revenue in 2019 and the number of on-going clinical trials as of the end of 2019, with a market share of 8.4% in 2019. It was also the only China-based clinical CRO among the top 10 global clinical CROs, ranking ninth with a global market share of 0.8% in terms of revenue in 2019 according to the Frost & Sullivan Report. The A Shares of its Company have been listed on the ChiNext market of the Shenzhen Stock Exchange (stock code: 300347) since August 2012. It offers (i) clinical trial solutions and (ii) clinical-related and laboratory services, primarily covering pre-clinical research to post-approval studies for drugs and medical devices.

For the year ended December 31, 2017, 2018 and 2019 and the three months ended March 31, 2020, the Company's net profits were RMB344.98 mn, RMB576.89 mn, RMB841.25 mn and RMB263.38 mn respectively.

Source

IPO Prospectus

Contact Us

Headquarters:	22/F, Manhattan Place, 23 Wang Tai Road, Kowloon Bay, Hong Kong	(852) 2287 8788
HK Services Centre:	6/F, May May Building, 683-685 Nathan Road, Mongkok, Kowloon	(852) 2748 0110
China Services Centre:	1004A(10/F), AVIC Center, 1018 Huafu Road, Futian District, Shenzhen	(86-755) 2216 5888
	2501, Tower A, China Overseas International Centre, 838 South Huangpi Road, Huangpu District, Shanghai	(86-21) 3227 9888
	6/F, Bank of Guangzhou Square, No. 30 East Zhujiang Road, TianHe District, Guangzhou	(020) 2812 0469
	Rm 2511, TBA Tower, 11 Dongguan Avenue, City East District, Dongguan	(86-769) 2223 0026

Declaration:

The above information is provided and distributed by CASH Financial Services Group Limited ("CASH"). The document is for reference only. Neither the information nor opinion expressed shall be construed, expressly or impliedly, as an advice, offer, invitation, advertisement, inducement, recommendation or representation of any kind or form whatsoever. While the information contained herein has been obtained from sources believed to be reliable, CASH or its affiliates do not represent that it is accurate or complete and it should be relied upon. CASH hereby expressly disclaims all liabilities arising out of or incidental to the accuracy and completeness of the contents and information herein contained. The contents and information in this document is subject to change without prior notice to you. Trade in securities covered by this report may be made only in those jurisdictions where the securities are qualified for trading. This document may not in whole or in part be reproduced or furnished to any person other than the addressee without written consent from CASH and CASH shall not be liable to any such third parties for loss arising from any unauthorized distribution. Securities dealing services are provided by Celestial Securities Limited, a corporation licensed to conduct Type 1 (dealing in securities) regulated activity under the Securities and Futures Ordinance.